Emad Shash
- Specialization: Oncologist/mammologist
- 20 years of experience
- Speaks:Arabic, English
- Online consultations: available
- Workplace: Egypt, Cairo, Shefaa Al Orman international oncology hospitals
- Participated in 70+ international oncology clinical trials; ESMO panel voting member.
Dr. Emad Shash is a medical oncologist who has participated in over 70 oncology clinical trials. He serves as the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. Dr. Shash specializes in systemic therapies, including chemotherapy, targeted therapy, and immunotherapy. He holds a Diploma in Hospital Quality Management and Patient Safety from JCI.
- Serves as an ESMO panel voting member and an ASCO committee member.
- Treats breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers.
- Former research physician and medical lead at the EORTC in Brussels.
- Works at Shefaa Al Orman, an ESMO-accredited oncology center treating 6,000 patients annually.
Online consultation with Emad Shash
Doctor's services
- Chemotherapy
- Hormone therapy
- Targeted therapy
- Immunotherapy with Keytruda (Pembolizumab)
- Chemotherapy for larynx cancer
- Chemotherapy for lung cancer
- Chemotherapy for uterine cancer
- Chemotherapy for gallbladder cancer
- Chemotherapy for ovarian cancer
- Chemotherapy for uterine cancer
- Immunotherapy for breast cancer
- Chemotherapy for testicular cancer
- Chemotherapy for kidney cancer
- Chemotherapy for esophageal carcinoma
- Chemotherapy for Sarcomas
- Immunotherapy for lung cancer
- Immunotherapy for kidney cancer
- Chemotherapy for stomach cancer
- Chemotherapy for pancreatic cancer
- Chemotherapy for breast cancer
- Chemotherapy for colon cancer
- Hormone therapy for prostate cancer
- Immunotherapy for prostate cancer
- Chemotherapy for prostate cancer
- Chemotherapy for liver cancer
- Immunotherapy
- Online Consultation with Oncologist
How are we doing?
Qualifications
Dr. Emad Shash is a medical oncologist and Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He has participated in 70+ international oncology clinical trials as a principal investigator and monitor. Dr. Shash uses systemic therapies including chemotherapy, targeted therapy, and immunotherapy. He also serves as a Scientific Advisor to the Egyptian Minister of Health and Population.
Specialization and Areas of Interest
Dr. Shash treats breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He also treats hemato-oncology cases. He uses systemic therapy to target cancer cells throughout the body. This involves precision methods like targeted therapy and immunotherapy. Additionally, he provides treatments like Keytruda to stimulate the immune system against tumors. Dr. Shash conducts detailed diagnosis and treatment planning for complex oncological conditions.
Medical Leadership and Research
Dr. Shash leads the Medical Oncology Department at Shifaa Al Orman Cancer Hospital. He served as the coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to over 70 international oncology trials. He performs studies in phases I, II, and III for global sponsors like Roche and Pfizer. The doctor also serves on the scientific board of the ECRIN.
Professional Experience
- 2018–present — Scientific Advisor to the Egyptian Minister of Health and Population
- 2016–present — Medical Director and General Manager, Breast Comprehensive Cancer Hospital, NCI
- 2016–present — Head of Medical Oncology and Breast Program Director, Shifaa Al Orman Hospital
- 2016–present — Deputy Medical Director, National Cancer Institute, Cairo University
- 2012–2015 — Clinical Research Physician & Medical Lead, EORTC, Brussels
- 2010–present — Staff Member, National Cancer Institute, Cairo University
- 2015–present — Clinical Research Development Consultant
- 2011–2012 — Associate Director for Junior Medical Staff training and Development, NCI, Cairo University
- 2010–2012 — Education and E-Learning Development Instructor and Consultant, National Cancer Institute
- 2010–2012 — Medical Oncology Course Instructor and Consultant, NCI and Nursing Technical Institute
- 2006–2010 — Resident, Department of Medical Oncology, The National Cancer Institute
- 2004–present — Medical Oncologist & Consultant Oncology clinic Private Centre, Cairo
Education and Training
- 1998–2004 — M.B.B.Ch, Cairo University Faculty of Medicine, Egypt
- 2010 — Master of Medical Oncology, National Cancer Institute, Cairo University
- 2015 — Doctorate of Medical Oncology & Hemato-Oncology, National Cancer Institute
- 2015 — EORTC Certificate of Excellence in Clinical Trials Methodology, Belgium
- 2017 — Diploma in Hospital Quality Management, Joint Commission International (JCI)
Memberships and Recognitions
- European Society of Medical Oncology (ESMO) – Panel Voting Member
- American Society of Clinical Oncology (ASCO) – International Affairs Committee
- Fellow of the European Institute of Oncology (EIO), Milan, Italy
- European Society of Gynecologic Oncology (ESGO)
- European Association of Cancer Education (EACE)
- Scientific board & founding member of C.A.I.R.O journal club, Cairo
- National Advisory Board member in Ain-shams Medical Students Research Association (AMSRA)
- Member of the Arab Medical Association against Cancer (AMAAC)
- Co-founder of the Egyptian Medical Sciences Foundation
Publications and Editorial Roles
Dr. Shash has published numerous articles in journals like Annals of Oncology and JCO Precision Oncology. He focuses on breast cancer quality indices and clinical trial methodology. From 2017 to 2021, he was an Associate Editor for the Journal of Egyptian National Cancer Institute. He also serves as a peer reviewer for several international scientific journals.
You may also be interested
Payment & Rewards
You don’t pay for our services
You make your payment directly at the clinic or to their official bank account.
Some clinics may require a deposit as a part of their policy.
Spread out your payments with installment options.
Earn rewards for referring friends to Bookimed.